K-STREET TRACKER
FOLLOW THE MONEY INTO THE SWAMP
Every federal lobbying filing tagged with a public-company ticker — who is spending, which firms they hire, and which members trade right around the filing.
Filings tracked
19,882
thru 2026-05-08
Total reported $
$2.7B
disclosed lobbying
Distinct clients
2,220
paying companies
Tickers targeted
1,207
public companies
💸 Top Spending Clients
| # | Client | Filings | Total $ |
|---|---|---|---|
| 1 |  PFIZER INC.PFE | 47 | $46.8M |
| 2 |  GENERAL MOTORS COMPANYGM | 61 | $46.8M |
| 3 |  META PLATFORMS INC. AND VARIOUS SUBSIDIARIESMETA | 12 | $44.9M |
| 4 | VISA INC.V | 45 | $37.7M |
| 5 |  AMAZON.COM SERVICES LLCAMZN | 36 | $32.8M |
| 6 |  LOCKHEED MARTIN CORPORATIONLMT | 73 | $29.0M |
| 7 |  FEDEX CORPORATIONFDX | 69 | $27.8M |
| 8 |  ELI LILLY AND COMPANYLLY | 56 | $27.1M |
| 9 |  ALTRIA CLIENT SERVICES LLCMO | 142 | $25.2M |
| 10 |  AMGEN INCAMGN | 19 | $24.9M |
| 11 |  COMCAST CORPORATIONCMCSV | 179 | $24.7M |
| 12 |  MERCK & CO INCMRK | 14 | $24.0M |
| 13 |  SOUTHERN COMPANYSO | 53 | $23.9M |
| 14 |  GOOGLE CLIENT SERVICES LLCGOOGL | 79 | $22.6M |
| 15 |  APPLE INCAAPL | 9 | $22.1M |
| 16 |  T-MOBILE USA INC.TMUS | 121 | $21.0M |
| 17 |  UNITEDHEALTH GROUP INCUNH | 19 | $20.4M |
| 18 |  VERIZON COMMUNICATIONS INC AND VARIOUS SUBSIDIARIESVZ | 40 | $20.1M |
| 19 |  OCCIDENTAL PETROLEUM CORPORATIONOXY | 30 | $19.7M |
| 20 |  MICROSOFT CORPORATIONMSFT | 103 | $18.8M |
| 21 |  QUALCOMM INCORPORATEDQCOM | 40 | $17.2M |
| 22 |  GENERAL DYNAMICS CORPGD | 11 | $17.0M |
| 23 |  BOEING COMPANYBA | 23 | $16.9M |
| 24 | THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)CI | 13 | $16.9M |
| 25 |  ORACLE CORPORATIONORCL | 58 | $16.7M |
🎯 Top Lobbied Tickers
| # | Ticker | Filings | Total $ |
|---|---|---|---|
| 1 | META Meta Platforms Inc. | 129 | $50.2M |
| 2 | PFE Pfizer Inc. | 87 | $48.6M |
| 3 | GM General Motors Company | 103 | $48.4M |
| 4 | V Visa Inc. | 46 | $37.7M |
| 5 | AMZN Amazon.com Inc. | 80 | $35.3M |
| 6 | LMT Lockheed Martin Corporation | 88 | $29.4M |
| 7 | FDX FedEx Corporation | 82 | $28.3M |
| 8 | LLY Eli Lilly and Company | 83 | $28.1M |
| 9 | AMGN Amgen Inc. | 95 | $28.0M |
| 10 | MRK Merck & Co. Inc. | 92 | $27.5M |
| 11 | AAPL Apple Inc. | 64 | $26.8M |
| 12 | GOOGL Alphabet Inc. Class A | 123 | $26.6M |
| 13 | MO | 164 | $26.2M |
| 14 | SO Southern Company | 108 | $26.1M |
| 15 | UNH UnitedHealth Group Inc. | 67 | $23.9M |
| 16 | VZ Verizon Communications Inc. | 116 | $23.8M |
| 17 | TMUS | 159 | $22.7M |
| 18 |  CHTR | 137 | $22.6M |
| 19 | GD General Dynamics Corporation | 127 | $22.5M |
| 20 |  TAT&T Inc. | 134 | $21.6M |
| 21 | ORCL Oracle Corporation | 132 | $20.6M |
| 22 | CMCSA Comcast Corporation | 141 | $20.4M |
| 23 | CI The Cigna Group | 64 | $19.9M |
| 24 | OXY Occidental Petroleum Corporation | 36 | $19.9M |
| 25 | MSFT Microsoft Corporation | 122 | $19.2M |
🆕 Filtered Filings · LLY
clear filters| Date | Ticker | Client | Registrant | Amount | Issue |
|---|---|---|---|---|---|
| 2026-04-20 | LLY | ELI LILLY AND COMPANY | TODD STRATEGY GROUP | $80K | Alzheimer's Disease. Anti Obesity Medication. Medicare/Medicaid Coverage and Reimbursement. PDUFA. 340B Program. |
| 2026-04-20 | LLY | ELI LILLY AND COMPANY | TARPLIN, DOWNS & YOUNG, LLC | $60K | IRA, non-interference, drug shortages, prescription drug access and affordability, transparency, insulin policy, drug pricing in federal programs Medicare & Medicaid payment and coverage issues, Medicare Part D, Medicare Part B, drug pricing in federal programs federal budget issues |
| 2026-04-20 | LLY | ELI LILLY & COMPANY | WILLIAMS AND JENSEN, PLLC | $50K | International and domestic tax issues. Implementation of PL 119-21. 340B Drug Pricing program, pharmaceutical supply chain, drug compounding and counterfeiting issues, PBM reform policies. Issues related to drug pricing; Issues related to reimbursement of insulin products; H.R. 4818/S. 2407 - Treat and Reduce Obesity Act of 2023, Issues related to the One Big Beautiful Bill Act (PL 119-21), most favored nation pricing polices. Accelerated approval pathway; support for Alzheimer's diagnostics; obesity treatment. Monitor Issues related to intellectual property protection and market access within current trade negotiations. Section 232 investigations and other tariff issues. Pharmaceutical IP issues, march-in rights. Issues related to pharmaceutical manufacturing and development. Drug importation, prescription drug safety, value and access. |
| 2026-04-20 | LLY | ELI LILLY AND COMPANY | MONUMENT ADVOCACY | $40K | Issues related to intellectual property protection, enforcement and market access issues within trade negotiations; supply chain management; issues related to China trade; Issues related to global health; and issues related to tariffs. Issues related to intellectual property protection, enforcement and market access issues within trade negotiations; supply chain management; issues related to China trade; Issues related to global health; and issues related to tariffs. |
| 2026-04-19 | LLY | ELI LILLY AND COMPANY FORMERLY REPORTED AS LILLY USA LLC | BROWNSTEIN HYATT FARBER SCHRECK, LLP | $90K | Issues related to the pharmaceutical industry Issues related to Inflation Reduction Act Implementation Treat and Reduce Obesity Act Pharmaceutical tariffs Safe Drugs Act Issues related to biotechnology legislation Diagnostic tests Clinical trial issues Issues related to supply chain |
| 2026-04-18 | LLY | ELI LILLY AND COMPANY | TIBER CREEK HEALTH STRATEGIES, INC. | $80K | |
| 2026-04-18 | LLY | TIBER CREEK HEALTH STRATEGIES INC. (ON BEHALF OF ELI LILLY AND COMPANY) | TIBER CREEK GROUP | $80K | Issues related to drug pricing and reimbursement for prescription drugs; Issues related to implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the One Big Beautiful Bill Act (PL 119-21). Issues related to drug pricing; Issues related to reimbursement of insulin products; Issues related to the One Big Beautiful Bill Act (PL 119-21); Issues related to compounding and H.R. 6509 - Safeguarding Americans from Fraudulent and Experimental (SAFE) Drugs Act of 2025; Issues related to FDA guidance on Alcohol Use Disorder (AUD). Issues related to intellectual property; Issues related to S. 1041 - Affordable Prescriptions for Patients Act; Issues related to patent thickets; Issues related to S. 1096 - Preserve Access to Affordable Generics and Biosimilars Act. |
| 2026-04-18 | LLY | ELI LILLY AND COMPANY FKA LILLY USA LLC | FORBES-TATE | $50K | Issues related to Insulin pricing; Issues related to the pricing of GLP-1 therapeutic products; Issues regarding the 340B Drug Pricing Program; Issues related to H.R. 5316 - Drug Shortage Compounding Patient Access Act of 2025; Issues related to H.R. 6509 - SAFE Drugs Act of 2025; Issues related to S. 3794 - SAFE Drugs Act of 2026. Issues regarding the Centers for Medicare and Medicaid Services National Coverage Decision (NCD) on Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer's Disease; Issues related to H.R. 4231/S. 1973 - Treat and Reduce Obesity Act of 2025; Issues related to H.R. 5316 - Drug Shortage Compounding Patient Access Act of 2025; Issues related to H.R. 6509 - SAFE Drugs Act of 2025; Issues related to S. 3794 - SAFE Drugs Act of 2026. Issues related to the report accompanying the FY 26 Senate Labor-HHS-Education Appropriations; Issues related to Rx drug pricing in the One Big Beautiful Bill Act (P.L. 119-21). |
| 2026-04-17 | LLY | ELI LILLY AND COMPANY | MARSHALL & POPP, LLC | $60K | Issues related to treatments for Alzheimers therapeutics. Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. Issues related to FDA regulation of pharmaceuticals. Issues related to the 340B program. |
| 2026-04-17 | LLY | ELI LILLY AND COMPANY | FEROX STRATEGIES | $60K | Issues related to the pharmaceutical industry. Issues related to treating and reducing obesity. Issues related to drug shortages and counterfeit products. |
| 2026-04-16 | LLY | ELI LILLY AND COMPANY | ELI LILLY AND COMPANY | $3.8M | Issues related to intellectual property protection and market access within current trade negotiations. Canada IP; USMCA implementation; Mexico patent linkage; Special 301; Trade talks: US-Japan, US-China, US-EU, US-UK, US-India, and US-Brazil; US Tariffs Patient protection; Pharmaceutical supply chain issues and shortages; Drug pricing, coverage, value, access and quality; Transparency; Intellectual property; Health insurance accessibility; Implementation of the "Inflation Reduction Act" (HR.5376); Prescription drug approval; Policy matters related to Artificial Intelligence in health care Intellectual property; 340B Program; Medicare & Medicaid prescription drug diagnosis and screening reimbursement pricing, coverage, value and access; Implementation of the "Inflation Reduction Act" (HR.5376); CMS National Coverage Determination on Alzheimer's disease Multi-lateral threats to IP and the biopharmaceutical industry; Drug importation; Prescription drug value, access and quality |
| 2026-04-16 | LLY | ELI LILLY AND COMPANY | GRV STRATEGIES LLC | $60K | Issues related to healthcare Issues related to trade |
| 2026-04-16 | LLY | ELI LILLY & COMPANY | DLA PIPER LLP (US) | $0 | |
| 2026-04-15 | LLY | ELI LILLY AND COMPANY | CHECKMATE GOVERNMENT RELATIONS | $120K | There is no specific bill filed. Engagement relates to issues on healthcare and trade. There is no specific bill filed. Engagement relates to issues on healthcare and trade. |
| 2026-04-15 | LLY | ELI LILLY AND COMPANY | VENN STRATEGIES | $50K | General Healthcare issues, including drug accessibility, importation and innovation policies. |
| 2026-04-14 | LLY | ELI LILLY & COMPANY | THE HARPLE GROUP, LLC | $10K | Monitored Issues and advised clients on matters related to Pharmaceutical supply chain security and resiliency. |
| 2026-04-09 | LLY | TIBER CREEK HEALTH STRATEGIES INC. ON BEHALF OF ELI LILLY AND COMPANY | B HALL STRATEGIES, LLC | $30K | Issues related to drug pricing. |
| 2026-01-20 | LLY | ELI LILLY AND COMPANY | CHECKMATE GOVERNMENT RELATIONS | $120K | There is no specific bill filed. Engagement relates to issues on healthcare and trade. There is no specific bill filed. Engagement relates to issues on healthcare and trade. |
| 2026-01-20 | LLY | ELI LILLY AND COMPANY | TODD STRATEGY GROUP | $80K | Alzheimer's Disease. Anti Obesity Medication. Medicare/Medicaid Coverage and Reimbursement. PDUFA. 340B Program. |
| 2026-01-20 | LLY | ELI LILLY AND COMPANY | GRV STRATEGIES LLC | $60K | Issues related to trade Issues related to healthcare |
| 2026-01-20 | LLY | ELI LILLY AND COMPANY | FEROX STRATEGIES | $60K | Issues related to the pharmaceutical industry. Issues related to treating and reducing obesity. Issues related to drug shortages and counterfeit products. |
| 2026-01-20 | LLY | ELI LILLY AND COMPANY | TARPLIN, DOWNS & YOUNG, LLC | $60K | Medicare & Medicaid payment and coverage issues, Medicare Part D, Medicare Part B, drug pricing in federal programs federal budget issues IRA, non-interference, drug shortages, prescription drug access and affordability, transparency, insulin policy, drug pricing in federal programs |
| 2026-01-20 | LLY | ELI LILLY AND COMPANY | VENN STRATEGIES | $50K | General Healthcare issues, including drug accessibility, importation and innovation policies. |
| 2026-01-20 | LLY | ELI LILLY & COMPANY | WILLIAMS AND JENSEN, PLLC | $50K | International and domestic tax issues. Implementation of PL 119-21. 340B Drug Pricing program, pharmaceutical supply chain, drug compounding and counterfeiting issues, PBM reform policies. Issues related to drug pricing; Issues related to reimbursement of insulin products; H.R. 4818/S. 2407 - Treat and Reduce Obesity Act of 2023, Issues related to the One Big Beautiful Bill Act (PL 119-21), most favored nation pricing polices. Accelerated approval pathway; support for Alzheimer's diagnostics; obesity treatment. Monitor Issues related to intellectual property protection and market access within current trade negotiations. Section 232 investigations and other tariff issues. Pharmaceutical IP issues, march-in rights. Issues related to pharmaceutical manufacturing and development. Drug importation, prescription drug safety, value and access. |
| 2026-01-20 | LLY | ELI LILLY AND COMPANY | MONUMENT ADVOCACY | $40K | Issues related to intellectual property protection, enforcement and market access issues within trade negotiations; supply chain management; issues related to China trade; Issues related to global health; and issues related to tariffs. Issues related to intellectual property protection, enforcement and market access issues within trade negotiations; supply chain management; issues related to China trade; Issues related to global health; and issues related to tariffs. |
| 2026-01-20 | LLY | ELI LILLY & COMPANY | DLA PIPER LLP (US) | $0 | |
| 2026-01-19 | LLY | TIBER CREEK HEALTH STRATEGIES INC. ON BEHALF OF ELI LILLY AND COMPANY | B HALL STRATEGIES, LLC | $30K | Issues related to drug pricing. |
| 2026-01-17 | LLY | TIBER CREEK HEALTH STRATEGIES INC. (ON BEHALF OF ELI LILLY AND COMPANY) | TIBER CREEK GROUP | $80K | Issues related to drug pricing and reimbursement for prescription drugs; Issues related to implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the One Big Beautiful Bill Act (PL 119-21). Issues related to drug pricing; Issues related to reimbursement of insulin products; Issues related to H.R. 4231/S. 1973 - Treat and Reduce Obesity Act of 2025; Issues related to the One Big Beautiful Bill Act (PL 119-21); Issues related to compounding and H.R. 6509 - Safeguarding Americans from Fraudulent and Experimental (SAFE) Drugs Act of 2025. Issues related to intellectual property; Issues related to S. 1041 - Affordable Prescriptions for Patients Act; Issues related to patent thickets; Issues related to S. 1096 - Preserve Access to Affordable Generics and Biosimilars Act. |
| 2026-01-17 | LLY | ELI LILLY AND COMPANY | TIBER CREEK HEALTH STRATEGIES, INC. | $80K | |
| 2026-01-16 | LLY | ELI LILLY AND COMPANY | MARSHALL & POPP, LLC | $60K | Issues related to treatments for Alzheimers therapeutics. Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. Issues related to FDA regulation of pharmaceuticals. Issues related to the 340B program. |
| 2026-01-15 | LLY | ELI LILLY AND COMPANY | ELI LILLY AND COMPANY | $2.2M | Issues related to intellectual property protection and market access within current trade negotiations. Canada IP; USMCA implementation; Mexico patent linkage; Special 301; Trade talks: US-Japan, US-China, US-EU, US-UK, US-India, and US-Brazil; US Tariffs Patient protection; Pharmaceutical supply chain issues and shortages; Drug pricing, coverage, value, access and quality; Transparency; Intellectual property; Health insurance accessibility; Implementation of the "Inflation Reduction Act" (HR.5376); Prescription drug approval; Policy matters related to Artificial Intelligence in health care; One Big Beautiful Bill Act (HR.1) Intellectual property; 340B Program; Medicare & Medicaid prescription drug reimbursement pricing, coverage, value and access; Implementation of the "Inflation Reduction Act" (HR.5376); CMS National Coverage Determination on Alzheimer's disease; One Big Beautiful Bill Act (HR.1) Multi-lateral threats to IP and the biopharmaceutical industry; Drug importation; |
| 2026-01-15 | LLY | ELI LILLY & COMPANY | THE HARPLE GROUP, LLC | $10K | Monitored Issues and advised clients on matters related to Pharmaceutical supply chain security and resiliency. |
| 2025-10-20 | LLY | ELI LILLY AND COMPANY | CHECKMATE GOVERNMENT RELATIONS | $120K | There is no specific bill filed. Engagement relates to issues on healthcare and trade. There is no specific bill filed. Engagement relates to issues on healthcare and trade. |
| 2025-10-20 | LLY | TIBER CREEK HEALTH STRATEGIES INC. (ON BEHALF OF ELI LILLY AND COMPANY) | TIBER CREEK GROUP | $80K | Issues related to drug pricing and reimbursement for prescription drugs; Issues related to implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the One Big Beautiful Bill Act (PL 119-21). Issues related to drug pricing; Issues related to reimbursement of insulin products; Issues related to H.R. 4231/S. 1973 - Treat and Reduce Obesity Act of 2025; Issues related to the One Big Beautiful Bill Act (PL 119-21); Issues related to compounding. Issues related to intellectual property; Issues related to S. 1041 - Affordable Prescriptions for Patients Act; Issues related to patent thickets; Issues related to S. 1096 - Preserve Access to Affordable Generics and Biosimilars Act. |
| 2025-10-20 | LLY | ELI LILLY AND COMPANY | TIBER CREEK HEALTH STRATEGIES, INC. | $80K | |
| 2025-10-20 | LLY | ELI LILLY AND COMPANY | MARSHALL & POPP, LLC | $60K | Issues related to treatments for Alzheimers therapeutics. Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. Issues related to FDA regulation of pharmaceuticals. Issues related to the 340B program. |
| 2025-10-20 | LLY | ELI LILLY AND COMPANY | FEROX STRATEGIES | $60K | Issues related to the pharmaceutical industry. Issues related to treating and reducing obesity. Issues related to drug shortages and counterfeit products. |
| 2025-10-20 | LLY | ELI LILLY AND COMPANY | VENN STRATEGIES | $50K | General Healthcare issues, including drug accessibility, importation and innovation policies. |
| 2025-10-20 | LLY | ELI LILLY & COMPANY | WILLIAMS AND JENSEN, PLLC | $50K | Issues related to pharmaceutical manufacturing and development. Drug importation, prescription drug safety, value and access. Issues related to drug pricing; Issues related to reimbursement of insulin products; H.R. 4818/S. 2407 - Treat and Reduce Obesity Act of 2023, Issues related to the One Big Beautiful Bill Act (PL 119-21), most favored nation pricing polices. Accelerated approval pathway; support for Alzheimer's diagnostics; obesity treatment. Monitor Issues related to intellectual property protection and market access within current trade negotiations. Section 232 investigations and other tariff issues. Pharmaceutical IP issues, march-in rights. International and domestic tax issues. H.R. 1, One Big Beautiful Bill Act implementation. 340B Drug Pricing program, pharmaceutical supply chain, drug compounding and counterfeiting issues, PBM reform policies. |
| 2025-10-20 | LLY | ELI LILLY AND COMPANY | MONUMENT ADVOCACY | $40K | Issues related to intellectual property protection, enforcement and market access issues within trade negotiations; supply chain management; issues related to China trade; Issues related to global health; and issues related to tariffs. Issues related to intellectual property protection, enforcement and market access issues within trade negotiations; supply chain management; issues related to China trade; Issues related to global health; and issues related to tariffs. |
| 2025-10-20 | LLY | TIBER CREEK HEALTH STRATEGIES INC. ON BEHALF OF ELI LILLY AND COMPANY | B HALL STRATEGIES, LLC | $30K | Issues related to drug pricing. Public Law 119-21: One Big Beautiful Bill Act. |
| 2025-10-16 | LLY | ELI LILLY AND COMPANY | ELI LILLY AND COMPANY | $3.4M | Issues related to intellectual property protection and market access within current trade negotiations. Canada IP; USMCA implementation; Mexico patent linkage; Special 301; Trade talks: US-Japan, US-China, US-EU, US-UK, US-India, and US-Brazil; US Tariffs Patient protection; Pharmaceutical supply chain issues and shortages; Drug pricing, coverage, value, access and quality; Transparency; Intellectual property; Health insurance accessibility; Implementation of the "Inflation Reduction Act" (HR.5376); Prescription drug approval; Policy matters related to Artificial Intelligence in health care Intellectual property; 340B Program; Medicare & Medicaid prescription drug reimbursement, coverage and value; Implementation of the "Inflation Reduction Act" (HR.5376); CMS National Coverage Determination on Alzheimer's disease Multi-lateral threats to IP and the biopharmaceutical industry; Drug importation; Prescription drug value, access and quality Pharmaceutical intellectual property iss |
| 2025-10-16 | LLY | ELI LILLY AND COMPANY | ELI LILLY AND COMPANY | $2.7M | Issues related to intellectual property protection and market access within current trade negotiations. Canada IP; USMCA implementation; Mexico patent linkage; Special 301; Trade talks: US-Japan, US-China, US-EU, US-UK, US-India, and US-Brazil; US Tariffs Patient protection; Pharmaceutical supply chain issues and shortages; Drug pricing, coverage, value, access and quality; Transparency; Intellectual property; Health insurance accessibility; Implementation of the "Inflation Reduction Act" (HR.5376); Prescription drug approval; Policy matters related to Artificial Intelligence in health care; One Big Beautiful Bill Act (HR.1) Intellectual property; 340B Program; Medicare & Medicaid prescription drug reimbursement pricing, coverage and value; Implementation of the "Inflation Reduction Act" (HR.5376); CMS National Coverage Determination on Alzheimer's disease; One Big Beautiful Bill Act (HR.1) Multi-lateral threats to IP and the biopharmaceutical industry; Drug importation; Prescrip |
| 2025-10-16 | LLY | ELI LILLY AND COMPANY | ELI LILLY AND COMPANY | $2.3M | Issues related to intellectual property protection and market access within current trade negotiations. Canada IP; USMCA implementation; Mexico patent linkage; Special 301; Trade talks: US-Japan, US-China, US-EU, US-UK, US-India, and US-Brazil; US Tariffs Patient protection; Pharmaceutical supply chain issues and shortages; Drug pricing, coverage, value, access and quality; Transparency; Intellectual property; Health insurance accessibility; Implementation of the "Inflation Reduction Act" (HR.5376); Prescription drug approval; Policy matters related to Artificial Intelligence in health care; One Big Beautiful Bill Act (HR.1) Intellectual property; 340B Program; Medicare & Medicaid prescription drug reimbursement pricing, coverage, value and access; Implementation of the "Inflation Reduction Act" (HR.5376); CMS National Coverage Determination on Alzheimer's disease; One Big Beautiful Bill Act (HR.1) Multi-lateral threats to IP and the biopharmaceutical industry; Drug importation; |
| 2025-10-16 | LLY | ELI LILLY AND COMPANY | ELI LILLY AND COMPANY | $1.9M | Issues related to intellectual property protection and market access within current trade negotiations. Canada IP; USMCA implementation; Mexico patent linkage; Special 301; Trade talks: US-Japan, US-China, US-EU, US-UK, US-India, and US-Brazil Patient protection; Pharmaceutical supply chain issues and shortages; Drug pricing, coverage, value, access and quality; Transparency; Intellectual property; Health insurance accessibility; Implementation of the "Inflation Reduction Act" (HR.5376); Prescription drug approval; Affordable Insulin Now Act (S.954/HR.1488), The INSULIN Act; Policy matters related to Artificial Intelligence in health care. Intellectual property; 340B Program; Medicare & Medicaid prescription drug reimbursement, coverage and value; Implementation of the "Inflation Reduction Act" (HR.5376); CMS National Coverage Determination on Alzheimer's disease; The INSULIN Act Multi-lateral threats to IP and the biopharmaceutical industry; Drug importation; Prescription drug v |
| 2025-10-16 | LLY | ELI LILLY AND COMPANY | TARPLIN, DOWNS & YOUNG, LLC | $60K | IRA, non-interference, drug shortages, prescription drug access and affordability, transparency, insulin policy, drug pricing in federal programs Medicare & Medicaid payment and coverage issues, Medicare Part D, Medicare Part B, drug pricing in federal programs federal budget issues |
| 2025-10-16 | LLY | ELI LILLY & COMPANY | DLA PIPER LLP (US) | $0 | |
| 2025-10-12 | LLY | ELI LILLY AND COMPANY | TODD STRATEGY GROUP | $80K | Alzheimer's Disease. Anti Obesity Medication. Medicare/Medicaid Coverage and Reimbursement. PDUFA. 340B Program. |
| 2025-10-09 | LLY | ELI LILLY AND COMPANY | GRV STRATEGIES LLC | $60K | Issues related to healthcare Issues related to trade |
| 2025-10-09 | LLY | ELI LILLY & COMPANY | THE HARPLE GROUP, LLC | $10K | Monitored Issues and advised clients on matters related to Pharmaceutical supply chain security and resiliency. |
| 2025-07-21 | LLY | ELI LILLY AND COMPANY | MARSHALL & POPP, LLC | $60K | Issues related to treatments for Alzheimers therapeutics. Issues related to prescription drug value, including H.R. 1, FY25 budget reconciliation, implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. Issues related to FDA regulation of pharmaceuticals. Issues related to the 340B program. |
| 2025-07-21 | LLY | ELI LILLY & COMPANY | WILLIAMS AND JENSEN, PLLC | $50K | International and domestic tax issues. OBBB. General education about policies impacting pharmaceutical development and approval. Policies impacting pharmaceutical research, development, and approval. Policies impacting public health preparedness and prevention, 340B Program. Accelerated Approval pathway; Alzheimers diagnostics policies. Pharmacy benefit manager reform proposals. H.R. 1; issues related to biopharmaceutical drug pricing, particularly related to MFN. Policies impacting Medicare Part D and Part B reimbursement policies. "Inflation Reduction Act of 2022" (PL 117-169) implementation. Pharmacy benefit manager reform proposals. Treat and Reduce Obesity Act of 2023. HR. 1, One Big Beautiful Bill Act, MFN drug pricing proposals. Accelerated approval pathway; support for Alzheimer's diagnostics; obesity treatment. Issues related to pharmaceutical manufacturing and development. Tariffs. Issues related to pharmaceutical manufacturing and development. |
| 2025-07-21 | LLY | ELI LILLY AND COMPANY | MONUMENT ADVOCACY | $40K | Issues related to intellectual property protection, enforcement and market access issues within trade negotiations; supply chain management; issues related to China trade; Issues related to global health; and issues related to tariffs. Issues related to intellectual property protection, enforcement and market access issues within trade negotiations; supply chain management; issues related to China trade; Issues related to global health; and issues related to tariffs. |
| 2025-07-21 | LLY | TIBER CREEK HEALTH STRATEGIES INC. ON BEHALF OF ELI LILLY AND COMPANY | B HALL STRATEGIES, LLC | $30K | Issues related to drug pricing in the One Big Beautiful Bill Act (PL 119-21). |
| 2025-07-21 | LLY | ELI LILLY & COMPANY | DLA PIPER LLP (US) | $0 | |
| 2025-07-20 | LLY | ELI LILLY AND COMPANY | CHECKMATE GOVERNMENT RELATIONS | $120K | There is no specific bill filed. Engagement relates to issues on healthcare and trade. There is no specific bill filed. Engagement relates to issues on healthcare and trade. |
| 2025-07-19 | LLY | ELI LILLY AND COMPANY | TODD STRATEGY GROUP | $80K | Alzheimer's Disease. Anti Obesity Medication. Medicare/Medicaid Coverage and Reimbursement. PDUFA. 340B Program. |
| 2025-07-18 | LLY | ELI LILLY AND COMPANY | TIBER CREEK HEALTH STRATEGIES, INC. | $80K | |
| 2025-07-18 | LLY | TIBER CREEK HEALTH STRATEGIES INC. (ON BEHALF OF ELI LILLY AND COMPANY) | TIBER CREEK GROUP | $80K | Issues related to drug pricing and reimbursement for prescription drugs; Issues related to implementation of the Inflation Reduction Act of 2022 (PL 117-169). Issues related to the One Big Beautiful Bill Act (PL 119-21). Issues related to drug pricing; Issues related to reimbursement of insulin products; Issues related to S. 1973 - Treat and Reduce Obesity Act of 2025; Issues related to the One Big Beautiful Bill Act (PL 119-21). Issues related to intellectual property; Issues related to S. 1041 - Affordable Prescriptions for Patients Act; Issues related to patent thickets; Issues related to S. 1096 Preserve Access to Affordable Generics and Biosimilars Act. |
| 2025-07-18 | LLY | ELI LILLY AND COMPANY | FEROX STRATEGIES | $60K | Issues related to the pharmaceutical industry. Issues related to Treating and Reducing Obesity. |
| 2025-07-18 | LLY | ELI LILLY AND COMPANY | VENN STRATEGIES | $20K | General Healthcare issues, including drug accessibility, importation and innovation policies. |
| 2025-07-17 | LLY | ELI LILLY AND COMPANY | ELI LILLY AND COMPANY | $2.7M | Patient protection; Pharmaceutical supply chain issues and shortages; Drug pricing, coverage, value, access and quality; Transparency; Intellectual property; Health insurance accessibility; Implementation of the "Inflation Reduction Act" (HR.5376); Prescription drug approval; Policy matters related to Artificial Intelligence in health care; One Big Beautiful Bill Act (HR.1) Intellectual property; 340B Program; Medicare & Medicaid prescription drug reimbursement pricing, coverage and value; Implementation of the "Inflation Reduction Act" (HR.5376); CMS National Coverage Determination on Alzheimer's disease; One Big Beautiful Bill Act (HR.1) Multi-lateral threats to IP and the biopharmaceutical industry; Drug importation; Prescription drug value, access and quality Pharmaceutical intellectual property issues Implementation and extension of the Tax Cuts and Jobs Act; Domestic manufacturing tax incentives; Expensing of research and development costs; Global minimum tax; Pension and |
| 2025-07-17 | LLY | ELI LILLY AND COMPANY | TARPLIN, DOWNS & YOUNG, LLC | $60K | IRA, non-interference, drug shortages, prescription drug access and affordability, transparency, insulin policy, 340B Medicare & Medicaid payment and coverage issues, Medicare Part D, Medicare Part B, 340B federal budget issues |
| 2025-07-15 | LLY | ELI LILLY AND COMPANY | GRV STRATEGIES LLC | $60K | Issues related to healthcare Issues related to trade |
| 2025-07-15 | LLY | ELI LILLY & COMPANY | THE HARPLE GROUP, LLC | $10K | Monitored Issues and advised clients on matters related to Pharmaceutical supply chain security and resiliency. |
| 2025-07-15 | LLY | TIBER CREEK HEALTH STRATEGIES INC. ON BEHALF OF ELI LILLY AND COMPANY | B HALL STRATEGIES, LLC | $0 | Issues related to drug pricing and reimbursement for prescription drugs. |
| 2025-04-21 | LLY | ELI LILLY AND COMPANY | TODD STRATEGY GROUP | $80K | Alzheimer's Disease. Anti Obesity Medication. Medicare/Medicaid Coverage and Reimbursement. PDUFA. 340B Program. |
| 2025-04-21 | LLY | ELI LILLY AND COMPANY | TARPLIN, DOWNS & YOUNG, LLC | $60K | IRA, non-interference, drug shortages, prescription drug access and affordability, transparency, insulin policy, 340B Medicare & Medicaid payment and coverage issues, Medicare Part D, Medicare Part B, 340B federal budget issues |
| 2025-04-21 | LLY | ELI LILLY AND COMPANY | VENN STRATEGIES | $50K | General Healthcare issues, including drug accessibility, importation and innovation policies. |
| 2025-04-21 | LLY | ELI LILLY & COMPANY | WILLIAMS AND JENSEN, PLLC | $50K | International and domestic tax issues. General education about policies impacting pharmaceutical development, approval and reimbursement. Policies impacting pharmaceutical research, development, and approval. Policies impacting public health preparedness and prevention and U.S. address to the Covid-19 pandemic, 340B Program. "Inflation Reduction Act of 2022" (PL 117-169). Accelerated Approval pathway; Alzheimers diagnostics policies. Pharmacy benefit manager reform proposals. Treat and Reduce Obesity Act of 2023. Policies impacting Medicare Part D and Part B reimbursement policies. Policies impacting pharmaceutical research, development, and approval. Policies impacting public health preparedness and prevention and U.S. address to the Covid-19 pandemic, "Inflation Reduction Act of 2022" (PL 117-169). Pharmacy benefit manager reform proposals. Treat and Reduce Obesity Act of 2023. Accelerated approval pathway; support for Alzheimer's diagnostics; obesity treatment. Issues relate |
| 2025-04-21 | LLY | ELI LILLY AND COMPANY | MONUMENT ADVOCACY | $40K | Issues related to intellectual property protection, enforcement and market access issues within trade negotiations; supply chain management; Issues related to China trade; Issues related to global health; and issues related to tariffs. Issues related to intellectual property protection, enforcement and market access issues within trade negotiations; supply chain management; Issues related to China trade; Issues related to global health; and issues related to tariffs. |
| 2025-04-21 | LLY | ELI LILLY AND COMPANY | CHECKMATE GOVERNMENT RELATIONS | $40K | There is no specific bill filed. Engagement relates to issues on healthcare and trade. There is no specific bill filed. Engagement relates to issues on healthcare and trade. |
| 2025-04-21 | LLY | ELI LILLY AND COMPANY | MARSHALL & POPP, LLC | $0 | Issues related to treatments for Alzheimers therapeutics. |
| 2025-04-21 | LLY | ELI LILLY & COMPANY | DLA PIPER LLP (US) | $0 | |
| 2025-04-17 | LLY | TIBER CREEK HEALTH STRATEGIES INC. (ON BEHALF OF ELI LILLY AND COMPANY) | TIBER CREEK GROUP | $80K | Issues related to drug pricing and reimbursement for prescription drugs; Issues related to implementation of the Inflation Reduction Act of 2022 (PL 117-169). Issues related to drug pricing; Issues related to reimbursement of insulin products; H.R. 4818/S. 2407 - Treat and Reduce Obesity Act of 2023. Issues related to intellectual property; S. 150 - Affordable Prescriptions for Patients Act of 2023; H.R. 6986/S. 3583 - A Bill to Address Patent Thickets. |
| 2025-04-17 | LLY | ELI LILLY AND COMPANY | TIBER CREEK HEALTH STRATEGIES, INC. | $80K | Issues related to implementation of drug pricing and reimbursement for prescription drugs in Inflation Reduction Act of 2022 (PL 117-169). |
| 2025-04-17 | LLY | ELI LILLY AND COMPANY | FEROX STRATEGIES | $60K | Issues related to the pharmaceutical industry. Issues related to Treating and Reducing Obesity. |
| 2025-04-17 | LLY | ELI LILLY & COMPANY | THE HARPLE GROUP, LLC | $10K | Monitored Issues and advised clients on matters related to Pharmaceutical supply chain security and resiliency. |
| 2025-04-16 | LLY | ELI LILLY AND COMPANY | ELI LILLY AND COMPANY | $3.4M | Issues related to intellectual property protection and market access within current trade negotiations. Canada IP; USMCA implementation; Mexico patent linkage; Special 301; Trade talks: US-Japan, US-China, US-EU, US-UK, US-India, and US-Brazil; US Tariffs Patient protection; Pharmaceutical supply chain issues and shortages; Drug pricing, coverage, value, access and quality; Transparency; Intellectual property; Health insurance accessibility; Implementation of the "Inflation Reduction Act" (HR.5376); Prescription drug approval; Policy matters related to Artificial Intelligence in health care Intellectual property; 340B Program; Medicare & Medicaid prescription drug reimbursement, coverage and value; Implementation of the "Inflation Reduction Act" (HR.5376); CMS National Coverage Determination on Alzheimer's disease Multi-lateral threats to IP and the biopharmaceutical industry; Drug importation; Prescription drug value, access and quality Pharmaceutical intellectual property iss |
| 2025-04-09 | LLY | ELI LILLY AND COMPANY | GRV STRATEGIES LLC | $60K | Issues related to healthcare Issues related to trade |
| 2025-03-27 | LLY | ELI LILLY AND COMPANY | CHECKMATE GOVERNMENT RELATIONS | $0 | Issues related to healthcare and trade. Issues related to healthcare and trade. |
| 2025-03-24 | LLY | ELI LILLY AND COMPANY | MARSHALL & POPP, LLC | $0 | Issues related to treatments for Alzheimers therapeutics. Issues related to treatments for Alzheimers therapeutics. Issues related to treatments for Alzheimers therapeutics. Issues related to treatments for Alzheimers therapeutics. |
| 2025-02-07 | LLY | ELI LILLY AND COMPANY | ELI LILLY AND COMPANY | $1.9M | Hospital discounts; 340B program; Prescription drug value, access, quality and compliance with Drug Quality and Safety Act Issues related to intellectual property protection and market access within current trade negotiations. Canada IP; USMCA implementation; Mexico patent linkage; Special 301; Trade talks: US-Japan, US-China, US-EU, US-UK, US-India, and US-Brazil Patient protection; Pharmaceutical supply chain issues and shortages; Drug pricing, coverage, value, access and quality; Transparency; Intellectual property; Health insurance accessibility; Implementation of the "Inflation Reduction Act" (HR.5376); Prescription drug approval; Affordable Insulin Now Act (S.954/HR.1488), The INSULIN Act; Policy matters related to Artificial Intelligence in health care. Intellectual property; 340B Program; Medicare & Medicaid prescription drug reimbursement, coverage and value; Implementation of the "Inflation Reduction Act" (HR.5376); CMS National Coverage Determination on Alzheimer's dis |